国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
INTERNATIONAL JOURNAL OF UROLOGY AND NEPHROLOGY
2014年
4期
536-539
,共4页
前列腺炎%骨盆痛
前列腺炎%骨盆痛
전렬선염%골분통
Prostatitis Pelvic%Pain
目的 观察评价坦索罗辛治疗慢性非细菌性前列腺炎/骨盆疼痛综合征的有效性及安全性.方法 收集2011年1月至2013年6月广州军区武汉总医院泌尿外科确诊为Ⅲ型前列腺炎患者100例,治疗前进行症状指数(NIH-CPSI)评分,按轻度(1～14)、中度(15 ～29)、重度(30 ～43)分成A、B、C三组.所有患者均给予坦索罗辛0.2mg,每晚睡前口服,连服8周,用药后第8周再次评估NIH-CPSI,记录不良反应,并进行统计学分析.结果 A、B、C三组平均NIH-CPSI评分由原来的24.3降至13.4(P＜0.01).治疗后疼痛不适评分与生活质量评分明显下降(P＜0.01),而排尿症状评分则下降不明显.三组患者随着症状严重程度的增加,坦索罗辛治疗的有效率逐渐递减,C组有效率与A组及B组有效率之间均有统计学差异.结论 坦索罗辛能够改善Ⅲ型前列腺炎患者的疼痛不适,提高患者生活质量,并且安全、副作用少,能够作为Ⅲ型前列腺炎的一线药物.
目的 觀察評價坦索囉辛治療慢性非細菌性前列腺炎/骨盆疼痛綜閤徵的有效性及安全性.方法 收集2011年1月至2013年6月廣州軍區武漢總醫院泌尿外科確診為Ⅲ型前列腺炎患者100例,治療前進行癥狀指數(NIH-CPSI)評分,按輕度(1～14)、中度(15 ～29)、重度(30 ～43)分成A、B、C三組.所有患者均給予坦索囉辛0.2mg,每晚睡前口服,連服8週,用藥後第8週再次評估NIH-CPSI,記錄不良反應,併進行統計學分析.結果 A、B、C三組平均NIH-CPSI評分由原來的24.3降至13.4(P＜0.01).治療後疼痛不適評分與生活質量評分明顯下降(P＜0.01),而排尿癥狀評分則下降不明顯.三組患者隨著癥狀嚴重程度的增加,坦索囉辛治療的有效率逐漸遞減,C組有效率與A組及B組有效率之間均有統計學差異.結論 坦索囉辛能夠改善Ⅲ型前列腺炎患者的疼痛不適,提高患者生活質量,併且安全、副作用少,能夠作為Ⅲ型前列腺炎的一線藥物.
목적 관찰평개탄색라신치료만성비세균성전렬선염/골분동통종합정적유효성급안전성.방법 수집2011년1월지2013년6월엄주군구무한총의원비뇨외과학진위Ⅲ형전렬선염환자100례,치료전진행증상지수(NIH-CPSI)평분,안경도(1～14)、중도(15 ～29)、중도(30 ～43)분성A、B、C삼조.소유환자균급여탄색라신0.2mg,매만수전구복,련복8주,용약후제8주재차평고NIH-CPSI,기록불량반응,병진행통계학분석.결과 A、B、C삼조평균NIH-CPSI평분유원래적24.3강지13.4(P＜0.01).치료후동통불괄평분여생활질량평분명현하강(P＜0.01),이배뇨증상평분칙하강불명현.삼조환자수착증상엄중정도적증가,탄색라신치료적유효솔축점체감,C조유효솔여A조급B조유효솔지간균유통계학차이.결론 탄색라신능구개선Ⅲ형전렬선염환자적동통불괄,제고환자생활질량,병차안전、부작용소,능구작위Ⅲ형전렬선염적일선약물.
Objectives To observe the validity and the safety of tamsulosin treating chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS).Methods One hundred patients who were confirmed as CPPS and treated in the department of urology of Wuhan general hospital of Guangzhou Command were enrolled from January 2011 to June 2013.ALL patients were accessed the NIH-Chronic prostatitis symptom index (NIH-CPSI) before the treatment,and they were divided into 3 groups by NIH-CPSI.Group A,group Band group C were classified as the scores of 1 ～ 14,15 ～ 29 and 30 ～ 43 respectively.ALL patients took 200mg tamsulosin every night,and re-evaluated the NIH-CPSI after 8 weeks.All side-effects were recorded.And all data was collected and the variables were compared.Results All average NIH-CPSI scores of three groups had declined from 24.3 to 13.4 (P ＜ 0.01).The pain score and the life quality score had significantly declined,while the urination score hadnt.Moreover,with the symptom increased,the rate of validity of tamsulosin decreased.Conclusions Tarnsulosin can modify pain and evaluate the life quality,and it is safe with little side effect.We recommend using tamsulosin as the main therapy for CP/CPPS.
